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Abstract
Background: Integrin-linked kinase (ILK) promotes tumor growth and invasion. Increased ILK
expression is correlated with progression of several tumor types, but the expression of ILK has not
been investigated in patients with non-small cell lung cancers (NSCLCs).
Methods:  We investigated ILK expression in patients with NSCLC by means of
immunohistochemistry.
Results: ILK expression was significantly associated with tumor grade, T status, lymph node
metastasis and stage. (p = 0.0169 for tumor grade; p = 0.0006 for T status; p = 0.0002 for lymph
node metastasis; p < 0.0001 for stage). The 5-year survival rates for patients with strong and weak
or no ILK expression levels were 20% and 59%, respectively: the difference was statistically
significant (p < 0.0001). A multivariate analysis of survival revealed that ILK expression, T status, N
status and vascular invasion were statistically significant prognostic factors (p = 0.0218 for ILK; p =
0.0046 for T status; p < 0.0001 for N status; p < 0.0001 for vascular invasion).
Conclusions: Our study demonstrates that increased expression of ILK is a poor prognostic
factor in patients with NSCLC.
Background
Interaction of cells with the extracellular matrix regulates
many physiological and pathological processes. These
interactions are mediated by a large family of cell surface
receptors known as integrins, which recognize several
extracellular matrix proteins, including fibronectin, colla-
gens, and vitronectin [1]. Integrins act as the bridge
between extracellular matrix components and the
cytoskeleton and other proteins, regulating cell survival,
proliferation, differentiation, and migration [1]. Integrins
are important mediators of tumor invasion and metastasis
through interaction with extracellular matrix. All integrins
are heterodimers composed of one copy each of two sub-
units, α and β. Many studies examined the association
between integrins and clinicalpathology or prognosis in
lung cancer. Reduced integrin α3β1 expression was
reported to be a factor of poor prognosis in pulmonary
adenocarcinoma [2]. Increased expression of integrin β1
was reported to be a poor prognosis in small cell lung can-
cer [3]. Integrin α5β1 was reported to be associated with
lymph node metastasis of non-small cell lung cancer
(NSCLC) [4], or to be a prognostic factor in node-negative
NSCLC [5].
Integrin-linked kinase (ILK) interacts with cytoplasmic
domain of both β1 and β3 integrins and is activated by
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cell- extracellular matrix interactions [6]. Overexpression
of ILK in epithelial cells results in anchorage-independent
cell growth with increased cell cycle progression [7]. Fur-
thermore, increased ILK expression is correlated with pro-
gression of several tumor types, including prostate [8],
gastric [9], and colon carcinomas [10]. However, to our
knowledge, the expression of ILK has not been investi-
gated in patients with NSCLC. Thus, we investigated ILK
expression in series of 134 cases of curatively resected
NSCLC by means of immunohistochemical assays to eval-
uate its clinical significance.
Methods
Patients
A total of 134 patients (88 men and 46 women; mean age,
65 years; age range, 28 to 80 years) with NSCLC were stud-
ied (consecutive cases). All patients in this study had
undergone curative tumor resection in our department
between 1995 and 1998. Patients who died within 30
days after surgery and those who underwent exploratory
thoracotomy were excluded from the study. Patients with
a past history of another type of cancer were also
excluded. With regard to histological type, 75 were aden-
ocarcinomas, 54 were squamous cell carcinomas and 5
were large cell lung carcinomas. The lesions of these 134
patients were staged on both operative and pathologic
findings according to the UICC TNM classification [11]
(1997). There were 36 patients (27%) with stage Ia, 37
(28%) with stage Ib, 3 (2%) with stage IIa, 18 (13%) with
stage IIb, and 40 (30%) with stage IIIa. None of the study
subjects received pre- or postoperative chemotherapy and
median follow-up of the patients was 75.3 months (range
60–96 months) and their outcomes were known.
Immunohistochemical staining
Resected tissue specimens were fixed in formalin, embed-
ded in paraffin, and cut into 3-µm serial sections. The sec-
tions were subjected to hematoxylin-eosin staining and
immunohistochemical analysis with ILK. A mouse anti-
ILK monoclonal antibody (Santa Cruz Biotechnology,
CA, USA) was used, and immunohistochemical staining
was based on the avidin-biotin-peroxidase complex
method and was performed with a Vestastatin kit (Vector,
Burlingame, CA). Negative control sections were treated
using nonspecific IgG in the primary antibody.
Determination of expression of ILK
Immunoreactivity was graded as from - to +++, according
to the number of cells stained. Grades was defined as fol-
low as: -, no positive cells; ±, less than 5% of tumor cells
showed immunoreactivity; +, 5–50% of tumor cells
showed immunoreactivity; ++, 50–80% of tumor cells
showed immunoreactivity; +++, over 80% of tumor cells
showed immunoreactivity. Grades ++ and +++ were
regarded as strong expression, and grades ± and + were
regarded as weak expression. The results of immunohisto-
chemical staining were evaluated independently by three
observers with no prior knowledge of patients' clinical
data. The evaluation was suitable for 96% of the samples.
The other specimens (4%) were re-evaluated independ-
ently, then classified according to the classification given
most frequently by the observers. In this study, we com-
pared the group of tumors of strong ILK expression with
the group of tumors of weak or no ILK expression.
Statistical analysis
The association between ILK expression and clinical data
was statistically evaluated by using Mann-Whitney U test
or the chi-square test. Survival curves were calculated by
the Kaplan-Meier method and were compared using the
log-rank test. The correlation of variables with survival
was analyzed by multivariate analysis using a Cox propor-
tional hazards model. All statistical analyses were per-
formed using the StatView software package (Abaracus
Concepts, Berkeley CA). A P value of <0.05 was consid-
ered statistically significant.
Results
Expression of ILK and clinicopathologic parameters
In non-neoplastic lung tissue, ILK was not detected in epi-
thelial cells, while ILK expression was found in stromal
cells including fibroblasts and infiltrating lymphocytes
(Figure 1). In the cancer cells of many patients, ILK expres-
sion was detected in both cytoplasm and nuclei (Figure 2,
and 3). Of the 134 patients, 6 (4%) were classified as -, 34
(25%) as ±, 53 (40%) as +, 25 (19%) as ++, and 16 (12%)
as +++. Patients with ILK ++ and +++ were placed together
in a strong ILK group and were compared with weak or no
ILK group. Tumor cells expressed ILK protein in most
NSCLC cases, and strong expression was detected 31%
(41 of 134) of the cases. Stromal cells in cancer lesion
were also positive to ILK, and rate of positive cells and
intensity of the staining were not different from those of
stromal cells in non-neoplastic lesion. As shown in Table
1, there were no significant differences between ILK
expression status and clinical factors of age, gender, histol-
ogy, lymphatic invasion and vascular invasion. However,
the expression of ILK protein was significantly associated
with tumor grade, T status, lymph node metastasis and
stage (p = 0.0169 for tumor grade; p = 0.0006 for T status;
p = 0.0002 for lymph node metastasis; p < 0.0001 for
stage).
Relationship between ILK expression and overall survival
The 5-year survival rates for the groups with strong, and
weak or no for ILK expression in their tumors were 20%
and 59% respectively: the difference was statistically sig-
nificant (p < 0.0001) (Figure 4). The univariate survival
analysis revealed that tumor grade, T status, N status,
stage, lymphatic invasion, vascular invasion and ILKBMC Cancer 2005, 5:1 http://www.biomedcentral.com/1471-2407/5/1
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expression all were statistically significant prognostic fac-
tors (p = 0.0003 for tumor grade; p < 0.0001 for T status;
p < 0.0001 for N status; p < 0.0001 for stage; p < 0.0001
for lymphatic invasion; p < 0.0001 for vascular invasion;
p < 0.0001 for ILk expression) (Table 2). However, age,
gender, and histology were not significant factors. The
multivariate survival analysis revealed that T status, N sta-
tus, vascular invasion and ILK expression were statistically
significant prognostic factors (p = 0.0046 for T status; p <
0.0001 for N status; p < 0.0001 for vascular invasion; p =
0.0218 for ILK expression) (Table 3).
Discussion
Recent studies have indicated that ILK facilitated the phos-
phorylation of AKT, which is required for AKT activation
[12]. Activation of AKT upregulates vascular endothelial
growth factor expression, and AKT is known to induce
angiogenesis and suppress apoptosis [12]. By regulating,
the activity of AKT as well as glycogen synthase kinase 3,
ILK facilitates the assembly and activity of the β-catenin/
LEF-1 transcription complex, and suppresses expression
of the invasion suppressor E-cadherin [13,14]. Overex-
pression of ILK in epithelial cells results in anchorage-
Table 1: Clinicopathologic characteristics of patients with NSCLC classified according to ILK
Characteristic Expression of ILK P-value
weak or none (n = 93) strong (n = 41)
Age
MEAN ± SD 64.6 ± 11.0 64.5 ± 9.3 0.3412
Gender
Male 57 31
Female 36 10 0.1077
Histology
Adenocarcinoma 54 21
Squamous cell ca. 37 17
Large cell ca. 2 3 0.4771
Tumor grade
Well differentiated 38 9
Mode differentiated 37 15
Poorly differentiated 18 17 0.0169
T status
T1 34 6
T2 49 20
T3 10 15 0.0006
Nodal status
N0 69 18
N1 7 1
N2 17 22 0.0002
Stage
Ia/Ib 62 11
IIa/IIb 14 7
IIIa 17 23 <0.0001
Lymphatic invasion
Negative 42 15
Positive 51 26 0.3548
Vascular invasion
Negative 56 19
Positive 37 22 0.1360BMC Cancer 2005, 5:1 http://www.biomedcentral.com/1471-2407/5/1
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independent cell growth with increased cell cycle progres-
sion, and constitutive up-regulation of cyclin D and cyclin
A expression [7]. Inhibition of ILK elicits cell cycle arrest
and induces apoptosis [15]. Overexpression of ILK in epi-
thelial cells induces tumorigenicity in nude mice, indicat-
ing that ILK can act as a proto-oncogene [16]. ILK is
associated with a highly invasive phenotype of certain
tumors [7].
In the current study, we detected ILK expression using
immunohistochemistry on tumors from patients with
NSCLC. ILK was strongly expressed in 31% of tumor sam-
ples, whereas there was no ILK expression in noncancer-
ous pulmonary tissue samples from the same patients,
except for fibroblasts and infiltrating lymphocytes. These
finding suggest that ILK expression may serve as a useful
marker of NSCLC. ILK is very low in healthy cells. In can-
cer cells, however, ILK activity is often increased, possibly
as a result of a malfunctioning of upstream components
in the integrin and growth factor signaling pathways. We
found a significant correlation between strong expression
and advanced T status, N status and stage. No correlation
was found age, gender or histology. These results suggest
that ILK expression is correlated with tumor progression
in NSCLC. Cases with strong ILK expression were reported
to be significantly more frequent in advanced gastric car-
cinoma [9]and advanced melanoma [17]. ILK-mediated
pathway that may enhance tumor progression is its regu-
lation on MMP expression [18]. During tumor progres-
sion, MMPs facilitate the pathological processes of tumor
invasion, angiogenesis, and metastasis by breaking down
the extracellular matrix. The overexpression of ILK has
been shown to be result of increased MMP-9 expression
[18]. We also demonstrated that the expression of ILK cor-
related with tumor grade. Recent studies have also linked
ILK expression to tumor grade of prostate [7], gastric [9]
or ovarian carcinomas [19]. The overall prognosis of
patients with strong ILK expression was significantly
poorer than that of patients with weak or no expression.
For stage I or stage II/IIIa patients, prognosis was poorer
for those with strong ILK expression than for those with
weak or no ILK expression, although the differences were
Immunohistochemical studies of ILK in non-neoplastic pul- monary tissue and in NSCLC tissue Figure 1
Immunohistochemical studies of ILK in non-neoplastic pul-
monary tissue and in NSCLC tissue. a non-neoplastic pulmo-
nary tissue: ILK was not detected in epithelial cells, while ILK 
expression was found in many stromal cells.
well differentiated adenocarcinoma: ILK protein was local- ized in both cytoplasms and nuclei Figure 2
well differentiated adenocarcinoma: ILK protein was local-
ized in both cytoplasms and nuclei. (Magnification, ×40 (Figure 
1), ×16 (Figure 2), and ×40 (Figure 3)).
well differentiated adenocarcinoma: ILK protein was local- ized in both cytoplasms and nuclei Figure 3
well differentiated adenocarcinoma: ILK protein was local-
ized in both cytoplasms and nuclei. (Magnification, ×40 (Figure 
1), ×16 (Figure 2), and ×40 (Figure 3)).BMC Cancer 2005, 5:1 http://www.biomedcentral.com/1471-2407/5/1
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Overall survival curves for patients classified according to expression of ILK Figure 4
Overall survival curves for patients classified according to expression of ILK. Five-year survival rates were 20% and 59% for 
patients in the strong ILK and weak or no ILK groups, respectively. A log-rank test revealed a significant difference between the 
two groups (p < 0.001).
Table 2: Univariate Analysis of Variables that Affected the Overall Survival Rate Determined by Cox Proportional Hazards Model
Variable Relative risk 95%CI p-value
Age (<65 yrs/65 yrs) 1.070 0.699–1.710 0.080
Gender (male/female) 1.537 0.866–2.383 0.1605
Histology (SCC/others) 1.174 0.688–2.005 0.5560
Tumor grade (mode., poor/well) 1.802 1.130–2.478 0.0003
T status (T2, T3/T1) 2.669 1.878–3.794 <0.0001
N status (N1, N2/N0) 5.911 3.600–9.705 <0.0001
Stage (stage II, III/Stage I) 8.143 4.851–12.255 <0.0001
Lymphatic invasion (positie/negative) 3.634 2.074–6.367 <0.0001
Vascular invasion (positive/negative) 3.198 1.974–5.181 <0.0001
ILK (strong/weak or no) 2.926 1.827–4.686 <0.0001BMC Cancer 2005, 5:1 http://www.biomedcentral.com/1471-2407/5/1
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not significant (data not shown). Strong expression of ILK
protein was reported to be significantly associated with
presence of nodal metastasis [9,17]. The univariate sur-
vival analysis revealed ILK expression was a significant
prognostic factor as well as T status, N status, stage, lym-
phatic invasion and vascular invasion. The status of ILK
expression might be dependent on the status of lymph
node metastasis or other variables. So the multivariate
analysis for survival was performed. In the current study,
the multivariate analysis revealed that ILK expression was
picked up for its independent level of prognostic signifi-
cance. Our results also showed that the tumors with a
strong expression of ILK were associated with an increased
recurrence, which suggests that patients with strong ILK
expression may be prone to metastasis, or may already
have occult systemic diseases. ILK expression level plays
one of the key roles in the biology of NSCLC and defines
a more aggressive tumor phenotype of NSCLC. Preopera-
tive adjuvant therapy in NSCLC is designed to improve
survival and reduce local recurrence. Recent reports have
shown that preoperative adjuvant therapy has led to an
increase in overall survival of NSCLC patients [20,21]. It
is possible that this preoperative adjuvant treatment
modality may be important for patients whose tumors
have strong ILK expression. In the future, small molecule
antagonists of ILK may be used to interfere with recur-
rence in tumor patients.
Conclusion
Our study demonstrates that ILK expression is a poor
prognostic factor in patients with NSCLC. Thus, the utility
of the expression of ILK could open up a new window for
the molecular marker and the treatment of NSCLC.
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